Women Rate Cannabis as More Rewarding Than Men — Even at the Same Dose

The Setup: Why No One Had Done This Properly

Cannabis research has a gender problem. Historically, clinical studies overenrolled men — sometimes dramatically. When women were included, the data were rarely analyzed by sex. And the few population surveys that did break down results by gender typically couldn't control for usage patterns. If men smoke more, any comparison of effects is contaminated by dose differences.

Cooper and Haney solved this by going back to their own data. They had run four separate double-blind, within-subject laboratory studies at Columbia, all following the same general protocol. Each study included both men and women. By pooling across all four and matching 35 women to 35 men on current cannabis use — same frequency (roughly 7 days/week), same daily quantity — they eliminated the dosing confounder that had hobbled every prior comparison.

The key detail: participants fasted overnight, arrived at 9 AM, provided carbon monoxide and urine samples to confirm abstinence, then smoked under observation. This wasn't a survey or a self-report study. These were controlled drug administrations in a clinical laboratory, with placebo conditions and repeated measures.

The Results: Same High, Different Reward

This pattern is the study's most important contribution: the dissociation between intoxication and reward. Both sexes felt equally high. Both showed the same physiological arousal. But women's brains coded the experience as more pleasurable and more worth repeating. In pharmacological terms, the abuse-related subjective effects diverged while the intoxicating and cardiovascular effects did not.

Under placebo conditions, there were no sex differences at all. The divergence only appeared when active cannabis was administered. This rules out a general tendency for women to rate experiences more positively — the effect was specific to the drug.

Why This Matters: The Telescoping Effect

The finding slots into a well-documented epidemiological pattern called the telescoping effect: women progress from first cannabis use to cannabis use disorder in a shorter timeframe than men. This has been observed across multiple substances — alcohol, opioids, cocaine — but the mechanism was poorly understood for cannabis.

Cooper and Haney's study doesn't prove the entire telescoping chain — it illuminates one specific link. If every cannabis session is slightly more rewarding for women, the cumulative reinforcement history builds faster. Over months and years, that differential compounding could explain the accelerated trajectory from use to disorder.

The Biology Underneath

Why would cannabis be more rewarding for women? The answer likely lies in the sexual dimorphism of the endocannabinoid system itself.

Rebecca Craft's landmark 2013 review in Life Sciences laid the preclinical foundation for these findings. In animal models, female rodents consistently show greater sensitivity to THC's effects — they self-administer more, develop conditioned place preference faster, and show greater analgesic responses. Ovariectomy reduces these differences; estradiol replacement restores them. The hormonal connection is not speculative — it's been demonstrated through systematic manipulation.

Cooper and Haney couldn't control for menstrual cycle phase in their pooled analysis (the original studies ran 4-8 weeks each without cycle tracking). This is simultaneously one of the study's biggest limitations and one of its most important implications: if the sex difference in reward is detectable even without controlling for cycle phase — averaged across whatever hormonal state participants happened to be in — the effect during peak estradiol periods could be substantially larger.

What People Get Wrong

Myth vs. Reality

✕Myth

Women get higher from cannabis than men.

✓Reality

Women did not feel more intoxicated in this study. The 'High' and 'Stimulated' ratings were identical between sexes. What differed was the reward value — how good it felt and whether they'd choose to use again. Being equally high but finding it more rewarding is a fundamentally different (and more concerning) pattern than simply being more intoxicated.

The Evidence

Cooper & Haney (2014): no sex differences in VAS 'High' or 'Stimulated' ratings; significant sex differences only in 'Good' (p<=0.05) and 'Take Again' (p<=0.05).

Cooper & Haney (2014), Drug Alcohol Depend

The distinction matters clinically. If women simply got higher, the solution would be straightforward: use less. But the finding is subtler and more challenging. At the same level of intoxication, women's reward circuits respond more strongly. Dose reduction might help — a lower dose could reduce the reward signal — but the underlying sensitivity difference would persist.

The Researchers

Ziva Cooper earned her PhD in biopsychology at the University of Michigan, studying abuse liability of opioids and cocaine in animal models, before completing a postdoctoral fellowship in Margaret Haney's Cannabis Research Laboratory at Columbia University. The shift from animal to human behavioral pharmacology — and from opioids to cannabinoids — positioned her uniquely to bridge preclinical sex-differences research with controlled human studies.

Cooper went on to become Research Director of the UCLA Cannabis Research Initiative, where she has continued to investigate sex-dependent effects across therapeutic and recreational contexts. Her 2017 review with Haney in Neuropsychopharmacology — "Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective" — became the definitive synthesis of the field, integrating preclinical, clinical, and epidemiological evidence into a framework that argues sex must be a standard variable in every cannabis study.

The Limitations That Matter

The potency issue deserves emphasis. Cannabis in 2014 was already far stronger than the 3-5% THC cigarettes NIDA provides for research. The average dispensary flower now exceeds 20% THC, and concentrates can reach 80-90%. Whether sex differences in abuse-related effects scale with dose, plateau, or reverse at higher potencies is one of the most clinically urgent unanswered questions in cannabis pharmacology.

The Bigger Picture: Why We're Still Flying Blind

In 2025, the FDA issued updated draft guidance on studying sex differences in clinical evaluation of medical products. The agency has required sex-specific analysis since 1993. Yet in cannabis research, this mandate has been largely ignored. A review of over 40 randomized controlled trials on medical cannabis found that very few evaluated sex-dependent efficacy, and even fewer examined sex-specific adverse effects.

This isn't just an academic oversight. As of 2024, over 50% of patients receiving medical cannabis licenses in many jurisdictions are women. If cannabis is more reinforcing for women at therapeutic doses, treatment protocols designed around male-dominated trial data may be systematically miscalibrated for half the patient population.

Cooper and Haney's study — modest in sample size, limited by NIDA's low-potency research supply — opened a door that the field has been slow to walk through. The data suggest we need sex-specific dosing guidelines, cycle-aware treatment protocols, and clinical trials that don't just include women but analyze their outcomes separately.

Frequently Asked Questions

Do women get higher from cannabis than men?

Not exactly. In Cooper and Haney's study, women did not feel more "High" or "Stimulated" than men. What differed was how rewarding the experience felt — women rated it as more "Good" and were more willing to "Take Again." The intoxication was the same; the enjoyment was different. This dissociation between intoxication and reward is actually more concerning from an addiction perspective than a simple dose-response difference would be.

Does this mean women are more likely to become addicted to cannabis?

This study provides one possible mechanism for why women progress to cannabis use disorder faster (the telescoping effect), but it doesn't prove causation. Enhanced rewarding effects could contribute to faster dependence development, but many factors — hormonal, social, psychological, genetic — also play roles. What the data do suggest is that sex should be considered a risk factor in CUD screening, not that every woman who uses cannabis will develop problems.

Should women use lower doses of cannabis?

The research suggests women may benefit from starting at lower doses, particularly for therapeutic use. Greater sensitivity to rewarding effects at the same dose implies that less may be needed to achieve desired outcomes — and that higher doses may accelerate tolerance and dependence pathways. This applies to microdosing approaches as well.

Did the study account for the menstrual cycle?

No, and this is one of its key limitations. Preclinical research shows that estradiol levels, which fluctuate across the menstrual cycle, modulate CB1 receptor sensitivity. The follicular phase (when estrogen is rising) may amplify cannabis's rewarding effects. Future studies need to track cycle phase to understand the full range of sex differences.

Does this study apply to edibles, vapes, or concentrates?

The study only tested smoked cannabis at low THC potencies (3.27-5.50%). Whether sex differences in reward hold for other routes, higher potencies, or CBD-containing products is unknown. Given that edibles undergo first-pass metabolism (producing the more potent 11-OH-THC), and that sex differences in liver enzyme activity are well-documented, the pharmacology could diverge further with oral administration.